Natural evolution of prostate cancer

被引:1
|
作者
Hugosson, J
Aus, G
机构
[1] Department of Urology, Göteborg University, S-416 85 Östra Hospital, Göteborg
关键词
D O I
10.1677/erc.0.0030147
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The course of untreated or only palliatively treated prostate cancer was studied in two large unselected populations. The first population comprised 514 patients (mean age 74 years at diagnosis) who were all followed to death and represented patients in different stages and grades at diagnosis. The second population included 490 men (mean age 68 years at diagnosis) with newly detected prostate cancer diagnosed during 1960 to 1980 and who survived for at least 10 years after diagnosis. Of the patients with stage M0 at diagnosis 50% ultimately died of prostate cancer. In early stage prostate cancer most deaths during the first 10 years were due to unrelated causes while prostate cancer was the dominant cause of death after 10 years. All the different stages and grades had an almost straight-falling cause-specific survival curve and all curves ended close to zero after 25 years. This means that prostate cancer deaths continue to occur as long as there are patients at risk and in none of the groups examined did the risk decline after a certain time. When a comparison was made with other studies on deferred treatment (corresponding subgroups were extracted) very similar results were found. However, the overall impression of the results looked very different when follow-up was extended from 10 to 25 years. Apart from a high mortality, a high morbidity was also found in patients who died from prostate cancer; this was significantly higher than in those who died of unrelated diseases. Patients at stage M0 at diagnosis who ultimately died had more frequent problems with local tumour growth than those who were at stage M1 at diagnosis. Early prostate cancer is usually a very slow-growing disease but it has a malignant potential and if the host lives long enough he will be at high risk for prostate cancer death irrespective of stage or grade at diagnosis.
引用
收藏
页码:147 / 155
页数:9
相关论文
共 50 条
  • [41] Focal therapy for prostate cancer: Revolution or evolution?
    Turpen R.
    Rosser C.J.
    BMC Urology, 9 (1)
  • [42] Re: Punctuated Evolution of Prostate Cancer Genomes
    Shaikhibrahim, Zaki
    Offermann, Anne
    Perner, Sven
    EUROPEAN UROLOGY, 2014, 65 (03) : 666 - 667
  • [43] Evolution of advanced technologies in prostate cancer radiotherapy
    Zaorsky, Nicholas G.
    Harrison, Amy S.
    Trabulsi, Edouard J.
    Gomella, Leonard G.
    Showalter, Timothy N.
    Hurwitz, Mark D.
    Dicker, Adam P.
    Den, Robert B.
    NATURE REVIEWS UROLOGY, 2013, 10 (10) : 565 - 579
  • [44] Evolution of the Concept of Focal Therapy for Prostate Cancer
    Tsivian, Matvey
    Abern, Michael R.
    Polascik, Thomas J.
    ONCOLOGY-NEW YORK, 2013, 27 (01): : 64 - +
  • [45] Evolution of Novel Biomarkers for Detection of Prostate Cancer
    Barbieri, Christopher E.
    JOURNAL OF UROLOGY, 2013, 190 (06): : 1970 - 1971
  • [46] Evolution of advanced technologies in prostate cancer radiotherapy
    Nicholas G. Zaorsky
    Amy S. Harrison
    Edouard J. Trabulsi
    Leonard G. Gomella
    Timothy N. Showalter
    Mark D. Hurwitz
    Adam P. Dicker
    Robert B. Den
    Nature Reviews Urology, 2013, 10 : 565 - 579
  • [47] Evolution, controversies and the future of prostate cancer grading
    Egevad, Lars
    Delahunt, Brett
    Yaxley, John
    Samaratunga, Hemamali
    PATHOLOGY INTERNATIONAL, 2019, 69 (02) : 55 - 66
  • [48] Is it necessary to cure prostate cancer when it is possible? (Understanding the role of prostate inflammation resolution to prostate cancer evolution)
    Wheeler, Ronald E.
    CLINICAL INTERVENTIONS IN AGING, 2007, 2 (01) : 153 - 161
  • [49] Molecular biology and prostate cancer: Evolution or revolution?
    Molinie, Vincent
    Beuzeboc, Philippe
    Mahjoub, Wafa K.
    ANNALES DE PATHOLOGIE, 2008, 28 (05) : 354 - 362
  • [50] Evolution of the Liquid Biopsy in Metastatic Prostate Cancer
    Moreno, Jose G.
    Gomella, Leonard G.
    UROLOGY, 2019, 132 : 1 - 9